ClinicalTrials.gg
Not yet recruitingNCT07120984IMAGLIOUpdated Aug 13, 2025

A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

A Phase 2 interventional study of L19TNF and L19TNF and TMZ in Glioma, sponsored by Philogen S.p.A.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Philogen S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.

Planned enrollment
40th of 104
52 · median 41
Started
2026
with 1 other
Phase 2
51 of 112
4 open now
Primary completion
2029-01
later than 10 of 17 live
Registered
107th of 112
by date

Among the 112 studies testing temozolomide in Glioma, this one is the 40th largest by planned enrollment of the 104 interventional ones that give a count, is one of 2 that started in 2026, is one of 51 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 107th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies testing temozolomide in Glioma, or all of them as a file.
02

Study summary

The purpose of this study is to explore the safety and efficacy of the antibody-cytokine fusion protein L19TNF alone or in combination with alkylating chemotherapy in patients with recurrent IDH mutant glioma.

Read the detailed description

This protocol describes an open label, multi-centric phase 2 study and patients will be treated with L19TNF at 13µg/kg as monotherapy or in combination with alkylating chemotherapy (Lomustine or Temozolamide) in different cohorts:

  • COHORT 1: L19TNF monotherapy in perioperative cohort of patients with recurrent astrocytoma or oligodendroglioma,
  • COHORT 2A: L19TNF Monotherapy for patients with recurrent oligodendroglioma,
  • COHORT 2B1: L19TNF plus TMZ for patients with recurrent oligodendroglioma,
  • COHORT 2B2: L9TNF plus CCNU for patients with recurrent oligodendroglioma,
  • COHORT 3A: L19TNF Monotherpay for patients with recurrent astrocytoma,
  • COHORT 3B1: L19TNF plus TMZ for patients with recurrent astrocytoma,
  • COHORT 3B2: L19TNF plus CCNU for patients with recurrent astrocytoma.

Eligibility criteria in this trial are:

  • Age ≥18
  • IDH-mutant glioma at first recurrence or progression after alkylating chemotherapy:
  • COHORT 1: Grade ≥2 oligodendroglioma or astrocytoma with planned resection
  • COHORT 2A, 2B1, 2B2: Grade ≥2 oligodendroglioma
  • COHORT 3A, 3B1, 3B2: Grade ≥2 astrocytoma
  • No therapy for first recurrence or progression after alkylating chemotherapy, except resection.
  • Patients must have measurable disease according to RANO 2.0
  • Karnofsky Performance Status (KPS) ≥ 70%.

The primary endpoint of the study is the Progression Free Survival Rate at 12 months (PFS-12).

The following secondary endpoints are considered:

  • Progression-free survival (PFS)
  • Overall response rate (ORR)
  • Disease control rate
  • Duration of response (DoR)
  • Overall survival (OS)
  • Safety and tolerability: adverse event (AE), serious AE (SAE), Drug-induced liver injury (DILI), physical examinations, echocardiography, ECG and standard laboratory parameters (hematology, biochemistry liver and urine analysis)
  • Human anti-factor antibodies (HAFA)
  • popPK
03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18
  2. IDH-mutant glioma (according to WHO 2021 classification) at first recurrence or progression after alkylating chemotherapy:

    • COHORT 1: Grade ≥2 oligodendroglioma or astrocytoma with planned resection, tumor tissue from prior resection must be available
    • COHORT 2A: Grade ≥2 oligodendroglioma
    • COHORT 2B1: Grade ≥2 oligodendroglioma previously treated with lomustine as monotherapy or in combination
    • COHORT 2B2: Grade ≥2 oligodendroglioma previously treated with temozolomide as monotherapy or in combination
    • COHORT 3A: Grade ≥2 astrocytoma
    • COHORT 3B1: Grade ≥2 astrocytoma previously treated with lomustine as monotherapy or in combination
    • COHORT 3B2: Grade ≥2 astrocytoma previously treated with temozolomide as monotherapy or in combination
  3. according to RANO 2.0 criteria.
  4. Documented IDH1 and/or IDH2 gene mutations detected by immunochemistry or sequencing.
  5. Performance Status (KPS) ≥ 70%.
  6. ≥ 3 months.
  7. Documented negative test for --. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  8. Female patients: female patients must be either documented not Women Of (WOCBP)* or must have a negative pregnancy test within 14 days of starting treatment. Additionally WOCBP must agree to use, from the screening to 6 months following the last study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.

    Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required from the screening to 6 months following the last administration of temozolomide, lomustine or L19TNF.

  9. Personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any therapy for recurrence/progression after alkylating chemotherapy, except resection.
  2. Therapy for glioma within 4 weeks of start of study treatment.
  3. Surgical resection of glioma within 4 weeks of start of study treatment.
  4. Stereotactic of glioma within 2 weeks of start of study treatment.
  5. Inability to undergo contrast-enhanced MRI.
  6. Known history of allergy to TNF or lomustine or temozolomide, any in the study medication or any other intravenously administered human proteins/peptides/antibodies.
  7. (ANC) \< 1.5 x 10\^9/L; \< 100 x 10\^9/L or (Hb) \< 9.0 g/dl.
  8. Chronically impaired renal function as indicated by \< 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance \< 45 mL/min/1.73m2.
  9. Inadequate liver function (, AST, ALP ≥ 2.5 x or total ≥ 1.5 x ULN).
  10. > 1.5 ULN.
  11. Any severe concomitant condition, which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
  12. Active or history of disease that might deteriorate when receiving an immuno-stimulatory agent, in the judgement of the investigator.
  13. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  14. Heart insufficiency (> Grade II, (NYHA) criteria).
  15. cardiac arrhythmias or requiring permanent medication.
  16. \< 55% or any other abnormalities observed during baseline and echocardiogram investigations that are considered clinically significant by the investigator. Patients with a marked prolongation of /QTc interval (e.g., repeated demonstration of QTc >470 milliseconds using Fredricia's QT correction formula) are excluded.
  17. Uncontrolled hypertension, defined by systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg.
  18. Arterial aneurism at high risk of rupture.
  19. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  20. Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders.
  21. Anxiety ≥ Grade 3.
  22. Severe diabetic retinopathy, such as severe non-proliferative retinopathy and proliferative retinopathy.
  23. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
  24. Known history of tuberculosis.
  25. Pregnancy or breast feeding.
  26. Requirement of chronic administration of high dose or other drugs. Subjects must have been either off steroids, or on a stable or decreasing dose ≤ 4 mg daily dexamethasone (or equivalent) for 7 days prior to start of treatment. Limited or occasional use of steroids to treat or prevent acute adverse reactions is not considered an exclusion criterion.
  27. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  28. Concurrent other than glioma unless the patient has been disease-free without intervention for at least 2 years.
  29. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  30. Serious, non-healing wound, ulcer or bone fracture.
  31. Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months.
  32. Anticoagulation therapy with P2Y12 antagonists (e.g., clopidogrel, ticagrelor) and vitamin K antagonists (e.g., phenprocoumon, warfarin).
  33. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
  34. Any within 4 weeks prior to treatment or plan to receive live vaccination during the study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    1: perioperative cohort of patients with recurrent astrocytoma or oligodendroglioma

    patients will be treated with 1 cycle (D1, D3 and D5) L19TNF before resection and 4 weeks after surgery

    Biological: L19TNF

  • Experimental
    2A:L19TNF Monotherapy for patients with recurrent oligodendroglioma

    patients with IDH-mutant oligodendroglioma, WHO Grade 2 or 3 at first progression after radiotherapy and one line of systemic chemotherapy, are treated with up to 6 cycles of 6 weeks with L19TNF

    Biological: L19TNF monothery in recurrent oligodendroglioma

  • Experimental
    2B1: L19TNF plus TMZ for patients with recurrent oligodendroglioma

    patients with IDH-mutant oligodendroglioma, WHO Grade 2 or 3 at first progression after radiotherapy and one line of systemic CCNU-based chemotherapy, are treated with L19TNF and temozolomide chemotherapy TMZ

    Biological: L19TNF and TMZ

  • Experimental
    2B2: L19TNF plus CCNU for patients with recurrent oligodendroglioma

    patients with IDH-mutant oligodendroglioma, WHO Grade 2 or 3 at first progression after radiotherapy and one line of systemic temozolomide chemotherapy, are treated with L19TNF and CCNU

    Biological: L19TNF and CCNU

  • Experimental
    3A: L19TNF monotherapy for patients with recurrent astrocytoma

    patients with IDH-mutant astrocytoma, WHO Grade 2, 3 or 4 at first progression after radiotherapy and one line of systemic chemotherapy, are treated with L19TNF

    Biological: L19TNF monotherapy

  • Experimental
    3B1: L19TNF plus TMZ for patients with recurrent astrocytoma

    patients with IDH-mutant astrocytoma, WHO Grade 2, 3 or 4 at first progression after radiotherapy and one line of systemic CCNU-based chemotherapy, are treated with L19TNF and temozolomide chemotherapy TMZ

    Biological: L19TNF and TMZ in recurrent astrocytoma

  • Experimental
    3B2: L19TNF plus CCNU for patients with recurrent astrocytoma

    patients with IDH-mutant astrocytoma, WHO Grade 2, 3 and 4 at first progression after radiotherapy and one line of systemic chemotherapy including temozolomide, are treated with L19TNFand CCNU

    Biological: L19TNF and CCNU in recurrent astrocytoma

Interventions

  • BiologicalL19TNF

    1 cycle of TNF before resection and 6 cycles after surgery

  • BiologicalL19TNF and TMZ

    Drug pages: Onfekafusp alfa · Temozolomide

    6 cycles of 28 days with L19TNF and TMZ

  • BiologicalL19TNF and CCNU

    Drug pages: Onfekafusp alfa · Lomustine

    6 cycles of 6 weeks of L19TNF and CCNU every 6 weeks

  • 6 cycles of 6 weeks with L19TNF

  • BiologicalL19TNF and TMZ in recurrent astrocytoma

    6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).

  • BiologicalL19TNF and CCNU in recurrent astrocytoma

    6 cycles of 6 weeks of L19TNF (D1, D3, D5, D22, D24 and D26) and CCNU (D1) every 6 weeks

  • 6 cycles of 6 weeks with L19TNF

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) in according to RECIST v.1.1. The duration is defined beginning from randomization to progression or death from any cause.

    Time frame: The PFS rate will be assessed at 12 months (PFS-12) in IDH mutant astrocytoma and in oligodendroglioma.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2029, 36 months later.

Of 131 phase 2 interventional studies under Glioma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 88. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 13, 2025
StartEst.
Jan 30, 2026
Primary completionEst.
Jan 30, 2029
CompletionEst.
Jan 30, 2029
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07120984
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Jan 30, 2026 (estimated)
Primary completion
Jan 30, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Aug 13, 2025

Study contacts

Teresa Hemmerle, PhD
Contact
regulatory@philogen.com
+390577017816
Concetta Aulicino, Pharmaceutical Chemist
Contact
regulatory@philogen.com
+390577017816

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Onfekafusp alfa · Temozolomide · Lomustine

Start the discussion